FDA sNDA Acceptance Puts Sarepta Therapeutics Stock in Focus Sarepta Therapeutics (SRPT) recently reported that the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion from accelerated to traditional approvals in Duchenne muscular dystrophy. This regulatory step, backed by Phase 3 ESSENCE data and real world evidence on efficacy trends and safety, gives investors a new reference point for evaluating Sarepta Therapeutics stock and its Duchenne...

In June 2026, Sarepta Therapeutics announced that the FDA accepted supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy exon-skipping therapies AMONDYS 45 and VYONDYS 53 to traditional approvals, with a PDUFA action date set for February 28, 2027. This move, backed by the ESSENCE confirmatory study and extensive real-world evidence across more than 1,800 treated patients, could be important for reinforcing the long-term regulatory footing of...

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.